Novo Nordisk wins approval for its weight-loss drug from China

Novo Nordisk A/S (CPH: NOVO-B) climbed 3.0% to an all-time high on Tuesday after China approved the sale of its weight-loss treatment Wegovy. Year-to-date, shares of the pharmaceutical giant are now up a whopping 45%. Why is it a big deal for Novo Nordisk stock? Novo Nordisk is yet to reveal the details of its

Source: Invezz